Invitation à la conférence de presse Novartis sur les résultats de l'exercice 2007
| Source: Novartis Pharma AG
Recommended Reading
-
Cosentyx® (secukinumab) becomes first and only IL-17A inhibitor approved in Europe for adults with PMR,1 a common inflammatory rheumatic disease with limited advanced treatment options2-6Approval...
Read More -
In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 vs placebo, with responses seen by Week 21SD is most prevalent type of chronic inducible...
Read More